Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$SRPT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.05 down -102.49% YoY • Reported revenue of $401.25M down -34.34% YoY • Sarepta Therapeutics narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and narrowed combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million for the full year.
2

Price since post

Full Details

Advertisement|Remove ads.